Adjuvant Screen Identifies Synthetic DNA-Encoding Flt3L and CD80 Immunotherapeutics as Candidates for Enhancing Anti-tumor T Cell Responses
Overcoming tolerance to tumor-associated antigens remains a hurdle for cancer vaccine-based immunotherapy. A strategy to enhance the anti-tumor immune response is the inclusion of adjuvants to cancer vaccine protocols. In this report, we generated and systematically screened over twenty gene-based m...
Main Authors: | Amy Haseley Thorne, Kirsten N. Malo, Ashley J. Wong, Tricia T. Nguyen, Neil Cooch, Charles Reed, Jian Yan, Kate E. Broderick, Trevor R. F. Smith, Emma L. Masteller, Laurent Humeau |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-02-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2020.00327/full |
Similar Items
-
The biology and targeting of FLT3 in pediatric leukemia
by: Colleen eAnnesley, et al.
Published: (2014-09-01) -
FLT3 and NPM1 gene mutations in patients with acute myeloid leukemias and the impact of FLT3-ITD mutations on the survival of patients with a normal karyotype
by: Irina Stepanovna Martynkevich, et al.
Published: (2010-12-01) -
Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia
by: Juanjuan Zhao, et al.
Published: (2019-09-01) -
Comparison of high-resolution melting analysis with direct sequencing for detection of FLT3-TKD, FLT3-ITD and WT1 mutations in acute myeloid leukemia
by: Aida Mahmoudi, et al.
Published: (2021-01-01) -
Autophagy activation mediates resistance to FLT3 inhibitors in acute myeloid leukemia with FLT3-ITD mutation
by: Dan Xu, et al.
Published: (2022-07-01)